222 related articles for article (PubMed ID: 18544666)
1. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Martin AP; Miller A; Emad L; Rahmani M; Walker T; Mitchell C; Hagan MP; Park MA; Yacoub A; Fisher PB; Grant S; Dent P
Mol Pharmacol; 2008 Sep; 74(3):807-22. PubMed ID: 18544666
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Martin AP; Mitchell C; Rahmani M; Nephew KP; Grant S; Dent P
Cancer Biol Ther; 2009 Nov; 8(21):2084-96. PubMed ID: 19823038
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
[TBL] [Abstract][Full Text] [Related]
5. OSU-03012 interacts with lapatinib to kill brain cancer cells.
Booth L; Cruickshanks N; Ridder T; Chen CS; Grant S; Dent P
Cancer Biol Ther; 2012 Dec; 13(14):1501-11. PubMed ID: 22990204
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Cruickshanks N; Hamed HA; Bareford MD; Poklepovic A; Fisher PB; Grant S; Dent P
Mol Pharmacol; 2012 May; 81(5):748-58. PubMed ID: 22357666
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Ling YH; Lin R; Perez-Soler R
Mol Pharmacol; 2008 Sep; 74(3):793-806. PubMed ID: 18524889
[TBL] [Abstract][Full Text] [Related]
9. p14(ARF)-induced apoptosis in p53 protein-deficient cells is mediated by BH3-only protein-independent derepression of Bak protein through down-regulation of Mcl-1 and Bcl-xL proteins.
Müer A; Overkamp T; Gillissen B; Richter A; Pretzsch T; Milojkovic A; Dörken B; Daniel PT; Hemmati P
J Biol Chem; 2012 May; 287(21):17343-17352. PubMed ID: 22354970
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
11. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Mukohara T; Civiello G; Johnson BE; Janne PA
Oncology; 2005; 68(4-6):500-10. PubMed ID: 16020981
[TBL] [Abstract][Full Text] [Related]
13. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
[TBL] [Abstract][Full Text] [Related]
15. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.
Gillissen B; Wendt J; Richter A; Richter A; Müer A; Overkamp T; Gebhardt N; Preissner R; Belka C; Dörken B; Daniel PT
J Cell Biol; 2010 Mar; 188(6):851-62. PubMed ID: 20308427
[TBL] [Abstract][Full Text] [Related]
16. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
17. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
18. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Singla S; Pippin JA; Drebin JA
Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
[TBL] [Abstract][Full Text] [Related]
19. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
20. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
Thakur V; Lu J; Roscilli G; Aurisicchio L; Cappelletti M; Pavoni E; White WL; Bedogni B
Oncotarget; 2017 Mar; 8(11):17887-17896. PubMed ID: 28060735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
